Brief: Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs
04/04/2025 01:15
April 4 (Reuters) - Mesoblast Ltd MSB.AX: MESOBLAST CELL THERAPY PRODUCTS NOT SUBJECT TO U.S. TARIFFS CELL THERAPY PRODUCTS NOT SUBJECT TO U.S. TARIFFS ALLOGENEIC CELLULAR PRODUCTS, INCLUDING RYONCIL AND REVASCOR, WILL NOT BE SUBJECT TO TARIFFS Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil